摘要
目的:探讨肺痿方离子导入对肺肾两虚型特发性肺纤维化患者肺功能及血清炎症因子的影响。方法:选取肺肾两虚型特发性肺纤维化患者36例,将其随机分为对照组与治疗组各18例,对照组采用西医常规治疗,治疗组在对照组基础上采用肺痿方离子导入治疗,观察两组患者的肺功能各项指标、血清炎症因子水平、临床疗效和不良反应情况。结果:治疗组肺功能各项指标均明显优于对照组(P<0.05),且血清炎症因子TGF-β1、MMP-9、IGF-1水平显著低于对照组(P<0.05),两组VEGF水平比较,差异无统计学意义(P>0.05)。治疗组总有效率明显高于对照组(P<0.05),两组不良反应均较少,组间差异无统计学意义(P>0.05)。结论:肺痿方离子导入治疗肺肾两虚型特发性肺纤维化患者的效果安全有效,对改善患者肺功能及抑制体内血清炎症因子的形成具有重要作用。
Objective： To explore the influence of Feiwei Fang iontophoresis on pulmonary function and serum inflammatory factors of patients with idiopathic pulmonary fibrosis of deficiency of lung and kidney. Methods： The 36 cases of patients with idiopathic pulmonary fibrosis of deficiency of lung and kidney were selected and divided into control and treatment groups randomly, 18 cases in each. The control group were treated with conventional western medicine, and the treatment group were treated with Feiwei Fang on the basis of the control group. Pulmonary function indicators, serum levels of inflammatory factors, clinical effect and adverse reactions were observed in the two groups. Results： The treatment group showed better pulmonary function indexes than the control group （P〈O.05）, as well as lower serum levels of TGF-1, MMP-9 and IGF-1 than those in the control group （P〈O.05）, and there was no significant difference on VEGF level between the two groups （P〉0.05）. The treatment group showed higher total effective rate than that of the control group （P〈0.05）. There were less adverse reactions in the two groups, with no significant difference （P〉0.05）. Conclusion： The effect is safe and effective of Feiwei Fang iontophoresis on patients with idiopathic pulmonary fibrosis of deficiency of lung and kidney. It plays an important role in improving lung function and inhibiting formation of serum inflammatory factors.
出处
《中医药导报》
2017年第11期112-114,共3页
Guiding Journal of Traditional Chinese Medicine and Pharmacy
